We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Removable Device Developed for Treatment of Type I Diabetes

By LabMedica International staff writers
Posted on 18 Jan 2018
A team of biomedical engineers has devised a novel technique for implantation and removal of living pancreatic beta cells in order to control insulin levels in patients with type I diabetes.

Cell encapsulation has been shown to hold promise for effective, long-term treatment of type I diabetes. More...
However, various obstacles have delayed the adaptation of this approach for clinical applications. For example, there is an unmet need for an encapsulation system that is capable of delivering sufficient cell mass while still allowing convenient retrieval or replacement.

To fill this gap, investigators at Cornell University (Ithaca, NY, USA) developed a simple cell encapsulation system that is readily scalable and conveniently retrievable. The key to this design was to engineer a highly wettable, Ca2+-releasing nanoporous polymer thread that promoted uniform in situ cross-linking and strong adhesion of a thin layer of alginate hydrogel around the thread. This method – named TRAFFIC (Thread-Reinforced Alginate Fiber for Islets enCapsulation) by the investigators - was used to implant hundreds of thousands of islet cells into animal diabetes models. The cells were protected by a thin hydrogel coating and the coated cells were attached to a polymer thread that could be removed or replaced easily when the cells had outlived their usefulness.

Results published in the December 26, 2017, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences revealed that the device provided immunoprotection of rat islets in immunocompetent C57BL/6 mice in a short-term (one-month) study, similar to neat alginate fibers. However, the mechanical property of the device, critical for handling and retrieval, was much more robust than the neat alginate fibers due to the reinforcement of the central thread. It also had facile mass transfer due to the short diffusion distance.

The investigators demonstrated the therapeutic potential of the device through the correction of chemically induced diabetes in C57BL/6 mice using rat islets for three months as well as in immunodeficient SCID-Beige mice using human islets for four months. They further showed, as a proof of concept, the scalability and retrievability of the device in dogs. After one month of implantation in dogs, the device could be rapidly retrieved through a minimally invasive laparoscopic procedure.

"The ability to remove the transplant is key because of its potential to form tumors," said senior author Dr. Minglin Ma, assistant professor biological and environmental engineering at Cornell University. "When they fail or die, they need to come out. You do not want to put something in the body that you cannot take out. With our method, that is not a problem."

Related Links:
Cornell University


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
image: ARIA can appear as brain swelling or small hemorrhages on MRI scans and remains difficult to predict before treatment begins (Reisa A, Sperling et al, via Wikimedia Commons, CC BY 4.0)

Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug

New antibody therapies for Alzheimer’s disease have shown promise in slowing disease progression, but their broader use has been limited by a common side effect known as amyloid-related imaging abnormalities (ARIA).... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.